ENTPD1 and neoplasm: Finally, engineered Treg approaches illustrate how tuning CD39 can modulate suppressive profiles: CAR-Tregs engineered with CD39 show reduced cytotoxicity and refined regulatory activity, suggesting avenues to fine-tune Treg biology for therapeutic ends—either to prevent autoimmunity or to counter tumor-promoting Tregs (25).